Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.47 |
| ▸ | JAK1 | P23458 | 3/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 2/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL582502 | 0.92 | PDE4B (0.62) | PDE4BADORA1 | |
| SCHEMBL583449 | 0.91 | PDE4B (0.49) | PDE4BADORA1JAK1JAK2JAK3 | |
| SCHEMBL583448 | 0.91 | PDE4B (0.49) | PDE4BADORA1JAK1JAK2JAK3 | |
| SCHEMBL583339 | 0.89 | PDE4B (0.57) | PDE4BADORA1JAK1JAK2JAK3 | |
| SCHEMBL583379 | 0.86 | PDE4B (0.74) | PDE4BADORA1ADORA2A | |
| SCHEMBL582494 | 0.85 | PDE4B (0.72) | PDE4B | |
| SCHEMBL582847 | 0.84 | PDE4B (0.71) | PDE4BADORA1 | |
| SCHEMBL582731 | 0.82 | PDE4B (0.47) | PDE4BADORA1JAK1JAK2JAK3 | |
| SCHEMBL583310 | 0.82 | ADORA1 (0.55) | PDE4BADORA1ADORA2A | |
| SCHEMBL582289 | 0.81 | PDE4B (0.69) | PDE4BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420666-B2 | Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2013-04-16 | — | — | US | disclosed |
| EP-2124944-B1 | Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors | RANBAXY LAB LTD (IN) | 2012-02-15 | — | — | EP | disclosed |
| US-20110130403-A1 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2011-06-02 | — | — | US | disclosed |
| US-20100292196-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292196-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE4A, PDE3A | PDE4B 5/4885ADORA1 1009/4885JAK1 249/4885 |
| US-20110130403-A1 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE3B, PDE4B | PDE4B 3/4885ADORA1 970/4885JAK1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.